[Angioedema].
Angioedema can be a symptom of anaphylaxis; it may be more hazardous that the circulatory collapse in otherwise healthy patients. Angioedema can be part of IgE- and histamine-mediated allergic reactions or part of NSAID-induced hypersensitivity with disturbances in arachidonic acid metabolism. If angioedema occurs without urticaria or other symptoms of anaphylaxis, it is usually mediated by increased bradykinin synthesis (HANE, EANE) or reduced metabolism (ACE inhibitors). These observations have led to new therapeutic approaches in HANE. Icatibant is a bradykinin-receptor-2 antagonist and blocks bradykinin-induced angioedema in HANE. How applicable this will be to ACE-inhibitor angioedema remains to be seen.
Merk
H F
HF
Universitäts-Hautklinik, RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany. hans.merk@post.rwth-aachen.de
D000707:Anaphylaxis / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D000799:Angioedema / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D054179:Angioedemas, Hereditary / Q000175:diagnosis / Q000188:drug therapy; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects; D001920:Bradykinin / Q000378:metabolism; D050718:Complement C1 Inhibitor Protein / Q000627:therapeutic use; D003176:Complement C3 / Q000378:metabolism; D003181:Complement C4 / Q000378:metabolism; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D006801:Humans
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D050718:Complement C1 Inhibitor Protein; D003176:Complement C3; D003181:Complement C4; D001920:Bradykinin